Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to regulatory approval in lung cancer, getting a green light in China for ...
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2 ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a holding subsidiary of Kelun Pharmaceutical, announced that the company has received a clinical trial notice approving the investigational new drug ...